Literature DB >> 2558889

Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana.

E Johansson1, M M Halldin, S Agurell, L E Hollister, H K Gillespie.   

Abstract

The terminal elimination half-life of delta 1-tetrahydrocannabinol (delta 1-THC) was investigated in eight men who were heavy users of marijuana. A stable isotope assay, following smoking deuterium-labeled delta 1-THC, was used to determine plasma concentrations. In two additional users plasma levels were followed after administration of unlabeled delta 1-THC. The subjects were asked to smoke a "loading dose" of 56 mg delta 1-THC during two days and then abstain from all marijuana use for 4 weeks. The pharmacokinetic behavior was consistent with a multicompartment model with a mean plasma elimination half-life of delta 1-THC of 4.3 days when concentrations were followed for 10-15 days after smoking. In the two subjects with detectable plasma levels during 4 weeks, half-lives of 9.6 and 12.6 days was obtained.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2558889     DOI: 10.1007/BF00679783

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

Review 1.  Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man.

Authors:  S Agurell; M Halldin; J E Lindgren; A Ohlsson; M Widman; H Gillespie; L Hollister
Journal:  Pharmacol Rev       Date:  1986-03       Impact factor: 25.468

2.  Stability, transfer and absorption of cannabinoid constituents of cannabis (hashish) during smoking.

Authors:  S Agurell; K Leander
Journal:  Acta Pharm Suec       Date:  1971-09

3.  Excretion patterns of cannabinoid metabolites after last use in a group of chronic users.

Authors:  G M Ellis; M A Mann; B A Judson; N T Schramm; A Tashchian
Journal:  Clin Pharmacol Ther       Date:  1985-11       Impact factor: 6.875

4.  Persistence of urinary marijuana levels after supervised abstinence.

Authors:  C A Dackis; A L Pottash; W Annitto; M S Gold
Journal:  Am J Psychiatry       Date:  1982-09       Impact factor: 18.112

5.  Extended least squares nonlinear regression: a possible solution to the "choice of weights" problem in analysis of individual pharmacokinetic data.

Authors:  C C Peck; S L Beal; L B Sheiner; A I Nichols
Journal:  J Pharmacokinet Biopharm       Date:  1984-10

6.  Tetrahydrocannabinol metabolism in man.

Authors:  L Lemberger
Journal:  Drug Metab Dispos       Date:  1973 Jan-Feb       Impact factor: 3.922

7.  Determination of delta 1-tetrahydrocannabinol in human fat biopsies from marihuana users by gas chromatography-mass spectrometry.

Authors:  E Johansson; K Norén; J Sjövall; M M Halldin
Journal:  Biomed Chromatogr       Date:  1989-01       Impact factor: 1.902

8.  Apparent half-life of excretion of cannabinoids in man.

Authors:  J S Cridland; D Rottanburg; A H Robins
Journal:  Hum Toxicol       Date:  1983-10

9.  Prolonged apparent half-life of delta 1-tetrahydrocannabinol in plasma of chronic marijuana users.

Authors:  E Johansson; S Agurell; L E Hollister; M M Halldin
Journal:  J Pharm Pharmacol       Date:  1988-05       Impact factor: 3.765

10.  Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis.

Authors:  J E Lindgren; A Ohlsson; S Agurell; L Hollister; H Gillespie
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

View more
  13 in total

1.  Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration.

Authors:  Garry Milman; Allan J Barnes; David M Schwope; Eugene W Schwilke; William D Darwin; Robert S Goodwin; Deanna L Kelly; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2010-06-08       Impact factor: 8.327

Review 2.  Human cannabinoid pharmacokinetics.

Authors:  Marilyn A Huestis
Journal:  Chem Biodivers       Date:  2007-08       Impact factor: 2.408

3.  The pitfalls of per se thresholds in accurately identifying acute cannabis intoxication at autopsy.

Authors:  Mary K Schwerdt; James R Gill
Journal:  Forensic Sci Med Pathol       Date:  2018-08-21       Impact factor: 2.007

Review 4.  A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics.

Authors:  Emily J Cox; Neha Maharao; Gabriela Patilea-Vrana; Jashvant D Unadkat; Allan E Rettie; Jeannine S McCune; Mary F Paine
Journal:  Pharmacol Ther       Date:  2019-05-07       Impact factor: 12.310

5.  Delta-9 THC can be detected and quantified in the semen of men who are chronic users of inhaled cannabis.

Authors:  Malinda S Lee; Andrea Lanes; Elizabeth S Ginsburg; Janis H Fox
Journal:  J Assist Reprod Genet       Date:  2020-04-30       Impact factor: 3.412

6.  Clinical Pharmacokinetics of Cannabinoids and Potential Drug-Drug Interactions.

Authors:  Marta Vázquez; Carlos García-Carnelli; Cecilia Maldonado; Pietro Fagiolino
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure.

Authors:  Ross H Lowe; Tsadik T Abraham; William D Darwin; Ronald Herning; Jean Lud Cadet; Marilyn A Huestis
Journal:  Drug Alcohol Depend       Date:  2009-07-23       Impact factor: 4.492

Review 9.  The pharmacokinetics and the pharmacodynamics of cannabinoids.

Authors:  Catherine J Lucas; Peter Galettis; Jennifer Schneider
Journal:  Br J Clin Pharmacol       Date:  2018-08-07       Impact factor: 4.335

10.  In vitro stability of free and glucuronidated cannabinoids in blood and plasma following controlled smoked cannabis.

Authors:  Karl B Scheidweiler; David M Schwope; Erin L Karschner; Nathalie A Desrosiers; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2013-03-21       Impact factor: 8.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.